PATENT Customer No. 22,852 Attorney Docket No. 09605.0012

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re A	application of:	)	
Emma	TERRICABRAS BELART et al.	)	Group Art Unit: Not yet assigned
Applic	ation No.: Not yet assigned	)	Examiner: Not yet assigned
Filed:	Herewith	)	
For:	4-AMINOTHIENO[2,3-d]PYRIMIDINE- 6-CARBONITRILE DERIVATIVES AS PDE7 INHIBITORS	)	Confirmation No.: Not yet assigned

being a U.S. National Phase of PCT/EP2004/000584

MAIL STOP: PCT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## **INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicants bring to the attention of the Examiner the documents on the attached listing. This Information Disclosure Statement is being filed within three months of the date of entry of the national stage in an international application.

Copies of the listed foreign and non-patent literature documents are attached.

The following applies to the attached non-English document:

WO 98/17668—Applicants are submitting herewith an esp@cenet abstract for this document. Applicants are also listing U.S. Patent No. 6,130,223 in the attached form PTO /SB/08, which is believed to be related to WO 98/17668.

Applicants respectfully requests that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material

or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,

GARRETT & DUNNER, J.L.,P.

Dated: July 21, 2005

By: (M) (Anthony C, Tridico

Reg. No. 45,958

301174 TO 21 JUL 2003

IDS Form PTO/	SB/08: Substitute for for	m 1449A/PTO		Complete if Known			
				Application Number 10/5/200			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			RE	Filing Date	Hereiwth 3000		
				First Named Inventor	Emma BELART-TERRICABRAS et al.		
			AI	Art Unit			
				Examiner Name			
Shoot	1 1	of	1	Attorney Docket Number	09605 0012		

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS							
Examiner	Cite		tssue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where		
Initials	No. <sup>1</sup>	Number-Kind Code <sup>2</sup> (if known)			Relevant Passages or Relevant Figures Appear		
		US-6,130,223	10/10/2000	Jonas et al.			
		US-					
		US-					
		US-	1				
		US-	<u> </u>				
		US-					
-		US-					
		US-					
		US-					
		US-	†				
		US-	<del>                                     </del>		<u> </u>		

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document  Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation <sup>6</sup>	
		EP 0 728 759	08/28/1996	Ono Pharmaceutical Co.			
		WO98/17668	04/30/1998	Merck		Abstract	

NON PATENT LITERATURE DOCUMENTS				
Examiner Cite Include name of Initials No.1 (book, magaz		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation <sup>6</sup>	
		esp@cenet Abstract for WO98/17668, published on April 30, 1998		

Examiner	 Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.